Sangamo Therapeutics services

Our investment in world-class manufacturing capabilities gives us the advantage of greater control over timelines, quality and supply for our robust pipeline. We have a state-of-the-art cGMP AAV manufacturing facility and trusted CDMO partner that together will support Sangamo’s diverse pipeline now, and in the future.

Sangamo is using groundbreaking science and novel technology to replace today’s symptomatic treatments with tomorrow’s genomic cures. We are pursuing programs across the spectrum of genomic medicine, with gene and cell therapies in the clinic today and preclinical programs in genome engineering and off-the-shelf cell therapy. Behind these are research efforts thoughtfully focused on leveraging our differentiated zinc finger technology. We are advancing a robust pipeline of wholly owned and partnered programs in rare disease, neurology, oncology and autoimmune indications with the goal of developing genomic medicines that transform the lives of patients.